Eli Lilly reached the FDA finish line with its cancer treatment Cyramza (ramucirumab), its star oncology candidate.
The full manufacturing implications of the complex three-way business swaps and sales that Novartis, GlaxoSmithKline and Eli Lilly announced today will take some time to sort out.
Novartis, GlaxoSmithKline and Eli Lilly have hammered out a pact to swap, sell and partner on a group of four different divisions, realigning the corporate and marketing landscape for each of the big three pharma players.
Novartis has agreed to sell its veterinary products business to Eli Lilly, whose Elanco unit is among the biggest players in animal health, for about $5.4 billion
The bull case for Eli Lilly and its long-stunted R&D operation rests largely on a potential string of FDA approvals for the much-hyped ramucirumab, and the Indiana drugmaker picked up its first, clearing the treatment to treat stomach cancer.
Drugmakers received the first slice of FDA social media guidance in January, and now the FDA's mailbag is filling up with letters on First Amendment protections, "jurisdictional creep" and other topics from the likes of Pfizer and PhRMA.
The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.
Teva Pharmaceutical Industries is one of half a dozen drugmakers that have been rolling out generics of Eli Lilly's top-selling blockbuster Cymbalta. The others are going to roll past the Israeli drugmaker after it recalled more than 1 million bottles of the antidepressant.
U.S. lawmakers have asked the U.S. Trade Representative's office to put Canada on a "priority watch list" because it has invalidated patents on drugs made by Eli Lilly and others.
One of the big surprises at the annual meeting of the American Association for Cancer Research last weekend belonged to none other than Eli Lilly, which will soon be able to add another therapy to its list of Phase III assets in the clinic.